因不良事件停用纳武利尤单抗联合伊匹木单抗的晚期黑色素瘤患者的疗效与安全性结局:随机II期和III期试验的汇总分析
该汇总分析纳入接受纳武利尤单抗1 mg/kg联合伊匹木单抗3 mg/kg(每3周一次共4剂,后续纳武利尤单抗单药3 mg/kg每2周一次)的晚期黑色素瘤患者(N=409)。因不良事件在诱导期停药者(n=96)与未因不良事件停药者(n=233)的疗效结局似乎相似:中位无进展生存期分别为8.4个月与10.8个月(P=.97),客观缓解率分别为58.3%与50.2%。作者认为即使停药,许多患者可能继续从联合治疗中获益。
要点
- 因不良事件在诱导期停药者与未因不良事件停药者的中位无进展生存期分别为8.4个月与10.8个月(P=.97)。
- 两组中位总生存期均未达到(P=.23),客观缓解率分别为58.3%与50.2%。
- 绝大多数3级或4级不良事件发生在诱导期,且多数经适当处理后缓解。
核心结论
- 因不良事件在诱导期停用纳武利尤单抗联合伊匹木单抗的患者与未因不良事件停药的患者疗效结局似乎相似,因此即使停药,许多患者可能继续从联合治疗中获益。
研究设计与样本
- 回顾性汇总分析,数据来自II期和III期随机试验中接受纳武利尤单抗1 mg/kg联合伊匹木单抗3 mg/kg(每3周一次共4剂,后续纳武利尤单抗单药3 mg/kg每2周一次)的患者(N=409)。
- 疗效评估人群为因不良事件在诱导期停药的全部随机分配患者(n=96)和未因不良事件停药者(n=233)。
- 安全性评估人群为因不良事件在任何时间停药的治疗患者(n=176)和未因不良事件停药者(n=231)。
主要发现
- 最短随访18个月时,因不良事件在诱导期停药者与未因不良事件停药者的中位无进展生存期分别为8.4个月与10.8个月(P=.97)。
- 两组中位总生存期均未达到(P=.23)。
- 因不良事件在诱导期停药者与未因不良事件停药者的客观缓解率分别为58.3%与50.2%。
- 绝大多数3级或4级不良事件发生在诱导期,且多数经适当处理后缓解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Approximately 40% of patients with advanced melanoma who received nivolumab combined with ipilimumab in clinical trials discontinued treatment because of adverse events (AEs). We conducted a retrospective analysis to assess the efficacy and safety of nivolumab plus ipilimumab in patients who discontinued treatment because of AEs. Methods Data were pooled from phase II and III trials of patients who received nivolumab 1 mg/kg plus ipilimumab 3 mg/kg, every 3 weeks for four doses, followed by nivolumab monotherapy 3 mg/kg every 2 weeks (N = 409). Efficacy was assessed in all randomly assigned patients who discontinued because of AEs during the induction phase (n = 96) and in those who did not discontinue because of AEs (n = 233). Safety was assessed in treated patients who discontinued because of AEs (n = 176) at any time and in those who did not discontinue because of AEs (n = 231). Results At a minimum follow-up of 18 months, median progression-free survival was 8.4 months for patients who discontinued treatment because of AEs during the induction phase and 10.8 months for patients who did not discontinue because of AEs ( P = .97). Median overall survival had not been reached in either group ( P = .23). The objective response rate was 58.3% for patients who discontinued because of AEs during the induction phase and 50.2% for patients who did not discontinue. The vast majority of grade 3 or 4 AEs occurred during the induction phase, with most resolving after appropriate management. Conclusion Efficacy outcomes seemed similar between patients who discontinued nivolumab plus ipilimumab treatment because of AEs during the induction phase and those who did not discontinue because of AEs. Therefore, even after discontinuation, many patients may continue to derive benefit from combination therapy.
引用
- Schadendorf D, Wolchok JD, Hodi FS, et al. Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. J Clin Oncol. 2017. PMID: 28841387. doi:10.1200/JCO.2017.73.2289
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。